Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a leader in the rapidly growing market for next-generation diagnostic tests utilizing comprehensive genomic information to improve cancer diagnosis and treatment decisions. With strong revenue growth, plans to expand overseas, and a promising product pipeline, Veracyte has the potential for sustained long-term revenue growth. Additionally, the company has a strong financial position with no debt and increasing cash flow. However, there are potential risks such as weaker than expected sales, lower margins, and free cash flow.

Bears say

Veracyte is facing significant competition in the genomic diagnostics market, and while their Prosigna and TrueMRD tests show potential, launch delays and slower than expected sales have hindered their growth potential. Additionally, the company's valuation is relatively high compared to industry peers, leaving little room for upside. Furthermore, potential risks such as weaker sales and lower margins pose a threat to the company's financial outlook.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.